Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Res ; 75(24): 5329-40, 2015 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-26631267

RESUMO

Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-positive cells for treating cancer. After internalization, ADCs with noncleavable linkers are catabolized to amino acid-linker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism. We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm. To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC. This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibody-maytansine ADCs, including ado-trastuzumab emtansine. In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation. Structure-activity experiments suggested that maytansine is a substrate for SLC46A3. Notably, SLC46A3 silencing led to relative increases in catabolite concentrations in the lysosome. Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens.


Assuntos
Antineoplásicos Fitogênicos/metabolismo , Imunoconjugados/metabolismo , Maitansina/metabolismo , Proteínas de Membrana Transportadoras/metabolismo , Antineoplásicos Fitogênicos/administração & dosagem , Linhagem Celular Tumoral , Citoplasma/metabolismo , Sistemas de Liberação de Medicamentos , Humanos , Imunoconjugados/administração & dosagem , Lisossomos/metabolismo , Maitansina/administração & dosagem
2.
PLoS One ; 8(10): e78726, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24205301

RESUMO

The DNA mismatch repair system (MMR) maintains genome stability through recognition and repair of single-base mismatches and small insertion-deletion loops. Inactivation of the MMR pathway causes microsatellite instability and the accumulation of genomic mutations that can cause or contribute to cancer. In fact, 10-20% of certain solid and hematologic cancers are MMR-deficient. MMR-deficient cancers do not respond to some standard of care chemotherapeutics because of presumed increased tolerance of DNA damage, highlighting the need for novel therapeutic drugs. Toward this goal, we generated isogenic cancer cell lines for direct comparison of MMR-proficient and MMR-deficient cells. We engineered NCI-H23 lung adenocarcinoma cells to contain a doxycycline-inducible shRNA designed to suppress the expression of the mismatch repair gene MLH1, and compared single cell subclones that were uninduced (MLH1-proficient) versus induced for the MLH1 shRNA (MLH1-deficient). Here we present the characterization of these MMR-inducible cell lines and validate a novel class of rhodium metalloinsertor compounds that differentially inhibit the proliferation of MMR-deficient cancer cells.


Assuntos
Linhagem Celular Tumoral , Reparo de Erro de Pareamento de DNA/genética , Proteínas Adaptadoras de Transdução de Sinal/deficiência , Proteínas Adaptadoras de Transdução de Sinal/genética , Antineoplásicos/química , Antineoplásicos/farmacologia , Células Clonais/patologia , Dano ao DNA , Reparo de Erro de Pareamento de DNA/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/genética , Técnicas de Silenciamento de Genes , Humanos , Instabilidade de Microssatélites/efeitos dos fármacos , Proteína 1 Homóloga a MutL , Proteínas Nucleares/deficiência , Proteínas Nucleares/genética , Compostos Organometálicos/química , Compostos Organometálicos/farmacologia , RNA Interferente Pequeno/genética , Ródio/química
3.
J Antimicrob Chemother ; 64(4): 829-36, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19679597

RESUMO

OBJECTIVES: To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens. METHODS: Clinical isolates of CF Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, Stenotrophomonas maltophilia, Burkholderia cepacia complex, Escherichia coli and Klebsiellia spp. were evaluated by MIC, MBC, post-antibiotic effect (PAE), synergy, time-kill, a rat pneumonia model and spontaneous mutation frequency (SMF). RESULTS: FTI showed high activity against E. coli, H. influenzae, S. aureus and Klebsiella spp. For the S. aureus strains, 75% of which were methicillin resistant (MRSA), FTI had a lower MIC(90) than tobramycin. For P. aeruginosa, FTI had a lower MIC(90) than fosfomycin, but tobramycin was more active than either. Synergy studies showed no antagonism between fosfomycin and tobramycin, and 93% of the isolates demonstrated no interaction. FTI was rapidly bactericidal and exhibited concentration-dependent killing in time-kill studies. In the rat pneumonia model, FTI and tobramycin demonstrated bactericidal killing of P. aeruginosa; both were more active than fosfomycin alone. The SMF for S. aureus resistance to FTI was 2-4 log(10) lower than that for tobramycin and 2-7 log(10) lower than that for fosfomycin. For P. aeruginosa, the FTI SMF was 2-3 log(10) lower than that for fosfomycin and 1-2 log(10) lower than that for tobramycin. CONCLUSIONS: FTI is a broad-spectrum antibiotic combination with high activity in vitro and in vivo. These data suggest FTI could be a potential treatment for respiratory infections caused by gram-positive and gram-negative aerobic bacteria.


Assuntos
Antibacterianos/uso terapêutico , Bactérias/efeitos dos fármacos , Fosfomicina/uso terapêutico , Pneumonia Bacteriana/tratamento farmacológico , Tobramicina/uso terapêutico , Administração por Inalação , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Bactérias/isolamento & purificação , Infecções Bacterianas/microbiologia , Bronquiectasia/complicações , Contagem de Colônia Microbiana , Combinação de Medicamentos , Interações Medicamentosas , Fosfomicina/administração & dosagem , Fosfomicina/farmacologia , Humanos , Pulmão/microbiologia , Masculino , Testes de Sensibilidade Microbiana , Viabilidade Microbiana , Ratos , Tobramicina/administração & dosagem , Tobramicina/farmacologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...